Clinical Trial Update: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating immunotherapy in patients with metastatic cancers harboring CDK12 mutations has completed and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Solid Tumor

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-01-30